24 May 2022
By Jonathan Nadler
CEO Jonathan Nadler talks UK Medical Cannabis in The Daily Express
Recently, LYPHE Group CEO and Co-Founder Jonathan Nadler spoke to Christopher Sharp at the Daily Express on medical cannabis, the challenges the industry faces and what the next steps need to be.
“1.4 million people roughly are consuming illegally for medical reasons. There should be a lot more of those patients that have access to legal medical cannabis, but they haven’t and that’s appalling”.
On the challenges facing access to medical cannabis as a form of medical treatment Jonathan said “ thousands of patients [in the UK] are consuming medicines that are prescribed by their doctors and they’re probably not working and not doing the job they should be doing.
Those patients aren’t being offered the alternative of medical cannabis, which I find just absolutely crazy particularly because 1.4 million people roughly are consuming illegally for medical reasons. There should be a lot more of those patients that have access to legal medical cannabis, but they haven’t and that’s appalling”.
There have been a wide range of professional studies that have found that cannabis based medicines are effective across a range of fields, including mental health and chronic pain.
Jonathan said these two areas are where Lyphe finds the most patients: “What we’re seeing is a real cross section of different types of patients coming to see us with conditions ranging from sleep focussed conditions all the way through to chronic pain.
“I think between psychiatry and pain, it probably accounts for 90 percent of the patients that we’re seeing.”
The Express comments that findings from these and other studies come at a time when the NHS has warned the UK faces a “second pandemic” of mental health in the aftermath of the COVID-19 pandemic; a role in which medicinal cannabis could have a part to play.
On the nature of the challenge faced Nadler agrees: “It’s become endemic, we are in the middle of something horrific when it comes to navigating mental health and I think what we’re seeing in the case of cannabis with a lot of our patients that come in with psychiatric conditions is they really are getting back their quality of life.”
LYPHE Group is passionate about the widening of access to medical cannabis, and has previously called for GP education, and prescription in the UK – as these are real barriers that prevent patients accessing treatment.
“That is the most important part of this, which is can we reduce that person’s suffering? Can they have a better quality of life and if the answer to those questions is yes that has to be worth looking at.”
These include the education of GPs, so they can feel confident in prescribing cannabis, and helping others to understand that cannabis in a medicinal setting can not only improve lives but save them.
Helping others is the main driver behind the campaign for the expansion of medicinal cannabis Nadler said: “That is the most important part of this, which is can we reduce that person’s suffering? Can they have a better quality of life and if the answer to those questions is yes that has to be worth looking at.”
You can read the interview in full at Express.co.uk